CN111840376A - Composition for treating chronic renal failure and preparation method thereof - Google Patents
Composition for treating chronic renal failure and preparation method thereof Download PDFInfo
- Publication number
- CN111840376A CN111840376A CN202010762747.6A CN202010762747A CN111840376A CN 111840376 A CN111840376 A CN 111840376A CN 202010762747 A CN202010762747 A CN 202010762747A CN 111840376 A CN111840376 A CN 111840376A
- Authority
- CN
- China
- Prior art keywords
- renal failure
- composition
- chronic renal
- treating chronic
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a composition for treating chronic renal failure and a preparation method thereof, wherein the composition comprises the following components in percentage by mass: 65 to 70 percent of natto powder; 5 to 8 percent of rhubarb; 13 to 15 percent of ligusticum chuanxiong hort; 10 to 15 percent of astragalus; the natto powder is produced by fermenting bacillus subtilis; the bacillus subtilis is named as Subtilisin-QK and is preserved in the national culture collection center (CCTCC) with the preservation number of CCTCC NO: m203078, the preservation date was 2003. The composition for treating chronic renal failure combines the natto powder with the traditional Chinese medicine components, takes the screened natto powder generated by fermenting the bacillus subtilis as the main component, and is mutually cooperated with the rhubarb, the ligusticum chuanxiong hort and the astragalus according to a specific proportion, so that the composition has an obvious effect of treating chronic renal failure; the composition for treating chronic renal failure has the advantages of simple formula, no toxic or side effect and wide application prospect.
Description
Technical Field
The invention relates to the technical field of biomedicine, in particular to a composition for treating chronic renal failure and a preparation method thereof.
Background
Renal failure can be classified into Acute Renal Failure (ARF) and Chronic Renal Failure (CRF). Acute renal failure is a clinical syndrome that occurs as a result of progressive decline in renal function due to various causes, and the prognosis is generally better after active treatment. If the kidney function may not be recovered and becomes chronic in the delayed treatment time, chronic renal failure is a serious stage of chronic renal insufficiency, which is a common cause of the continuous development of various kidney diseases, and is also called uremia. Once uremia is diagnosed, only two routes are available for treatment, dialysis or kidney transplantation. Kidney transplantation, which can bring better quality of life to patients, is currently the best method for treating renal failure, unfortunately, the number of organ donors is far lower than that of demanders, and the high medical costs and the health impact of organ rejection associated with organ transplantation are unpredictable.
The causes of chronic renal failure are: renal affection: such as various chronic glomerulonephritis, interstitial nephritis and secondary glomerular diseases. ② diabetes mellitus: since the incidence of diabetes is increasing year by year, chronic renal failure caused by diabetes is on the rise at present, for example, the development of kidney diseases is accelerated due to poor blood sugar control, and the kidney is affected by diabetes for 10 to 15 years, so that the control of blood sugar is very important. ③ hypertension: hypertension, like diabetes, causes kidney damage and poor blood pressure control, which accelerates the progression of kidney disease. Drug-induced kidney damage: many people often take some analgesics or Chinese medicines due to symptoms such as headache or general discomfort, and some components of the medicines have toxic effect on the kidney. Fifthly, other: still other systemic diseases can also cause chronic renal failure, such as gout.
The proportions of diabetes and hypertension in the causes of chronic renal failure have increased year by year. Diabetes and uremia have been reported to be the most common cause of chronic renal failure in patients over 40 years of age among developing families, accounting for 36.5%. Chronic nephritis is the main reason of uremia hemodialysis, the best method for treating chronic renal failure is to perform intervention treatment on diseases in the early stage of chronic renal failure, and as the early stage of chronic renal failure has no symptoms and signs, most patients have a late stage of uremia after the first visit, so that the medicines are directly used for treating the diseases after the chronic renal failure is pathological changes in the market at present, and the medicine treatment effect is not ideal. Aiming at the current market situation, the research and development of a health care product or a medicine which can be taken for a long time and has better effect for treating chronic renal failure is urgently needed.
Disclosure of Invention
In order to overcome the above-mentioned disadvantages of the prior art, the present invention is directed to a composition for treating chronic renal failure and a method for preparing the same.
In order to solve the problems, the invention adopts the following technical scheme:
a composition for treating chronic renal failure comprises the following components in percentage by mass:
the natto powder is produced by fermenting bacillus subtilis; the bacillus subtilis is named as Bacillus subtilis QK02, is preserved by China Center for Type Culture Collection (CCTCC), is located in Wuhan Hubei, has the preservation number of CCTCC NO: M203078, and has the preservation date of 11/17/2003.
Preferably, the activity of the natto powder is more than 80000 IU/g.
Preferably, the natto powder is prepared by the following process:
preparing a peptone culture medium, and adding the following components in percentage by mass into the culture medium: 2% of peptone, 2% of glucose, 1% of disodium hydrogen phosphate, 0.1% of sodium dihydrogen phosphate, 0.05% of magnesium sulfate, 0.02% of anhydrous calcium chloride, 0.1% of defoaming agent and the balance of water, and sterilizing at 115 ℃ for 30min for later use;
inoculating 1-3% of bacillus subtilis by weight into the peptone culture medium, and fermenting for 24h at 25-35 ℃;
and removing impurities from the fermentation liquor, concentrating, and then performing spray drying to obtain the natto powder.
The invention also provides a preparation method of the composition for treating chronic renal failure, which comprises the following steps:
grinding the natto powder, the rhubarb, the ligusticum chuanxiong hort and the astragalus membranaceus into powder, sieving the powder, and mixing the powder according to a proportion to obtain the composition for treating chronic renal failure.
Preferably, the mesh number of the sieve is 80-100 meshes.
The invention also provides an application of the composition for treating chronic renal failure in treating chronic renal failure, wherein the composition for treating chronic renal failure comprises the following components in percentage by mass:
the natto powder is produced by fermenting bacillus subtilis; the bacillus subtilis is named as Bacillus subtilis QK02, is preserved by China Center for Type Culture Collection (CCTCC), is located in Wuhan Hubei, has the preservation number of CCTCC NO: M203078, and has the preservation date of 11/17/2003.
The invention also provides a medicament, which is characterized by comprising the composition for treating chronic renal failure.
Preferably, the medicament further comprises any one or a combination of at least two of a pharmaceutically acceptable carrier, excipient or diluent.
Compared with the prior art, the invention has the technical effects that:
the composition for treating chronic renal failure combines the natto powder with the traditional Chinese medicine components, takes the screened natto powder generated by fermenting the bacillus subtilis as the main component, and is mutually cooperated with the rhubarb, the ligusticum chuanxiong hort and the astragalus according to a specific proportion, so that the composition has an obvious effect of treating chronic renal failure; the composition for treating chronic renal failure has the advantages of simple formula, no toxic or side effect and wide application prospect.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
The embodiment of the invention provides a composition for treating chronic renal failure, which comprises the following components in percentage by mass:
wherein the natto powder is produced by fermenting bacillus subtilis; the Bacillus subtilis is named as Bacillus subtilis QK02, is preserved by China Center for Type Culture Collection (CCTCC) and is positioned in Wuhan Hubei, the preservation number is CCTCC NO: M203078, and the preservation date is 11/17 days 2003.
The action mechanism of natto powder is as follows: the adopted natto powder is produced by fermenting bacillus subtilis separated from soybeans in a fermentation tank by using soybean peptone, glucose, trace metal elements, inorganic salt ions and the like, and fermented components are obtained by centrifuging, filtering, concentrating, spraying, drying and the like the fermentation liquor. The spray-dried component is mainly nattokinase, which also contains saponin, isoflavone, unsaturated fatty acid, lecithin, folic acid, edible fiber, calcium, iron, potassium, vitamins, various amino acids and minerals. The nattokinase has the main effects of dissolving thrombus, has obvious effects of reducing blood sugar, blood fat and the like, and has the effects of protecting blood vessels, kidney and the like.
The action mechanism of rhubarb is as follows: clear the intestines, relax the bowels, purge fire and remove toxicity. Radix et rhizoma Rhei can improve azotemia and hyperphosphatemia and hypocalcemia; inhibiting oxygen free radicals, inhibiting production of molecular toxins such as methylguanidine, guanidinosuccinic acid; compensatory hypertrophy affecting residual renal tissue; reducing hypermetabolic state of residual kidney; correcting lipid metabolism disorders; reduce proteinuria, inhibit angiotensin converting enzyme, and prevent and treat glomerulosclerosis with rhein. The rhubarb can inhibit the growth of mesangial cells, inhibit the proliferation of human kidney fibroblasts and the expression and synthesis of fibronectin, reduce the expression level of collagen alpha in kidney tissues, reduce the expression of alpha-SMA, reduce the aggregation of collagen and inhibit the transdifferentiation of epithelial cells. Pathological changes can be regulated and controlled at the early stage of glomerulosclerosis through the activity of F2kB and caspase23, and the reduction of caspase23 expression can be one of molecular mechanisms of rhein for reducing the apoptosis of glomerulosclerosis cells. Effects on renal microcirculation CRF patients have glomerular coagulation and increased blood viscosity at different degrees, and the filtration rate of glomeruli, blood plasma flow of rats and renal blood flow of CRF are remarkably increased by inhibiting synthesis of cyclooxygenase metabolites and resisting thrombosis of radix et rhizoma Rhei.
The action mechanism of the ligusticum chuanxiong hort is as follows: inhibiting platelet activation, aggregation and release responses, blocking renal injury caused thereby; improving microcirculation, improving renal tissue ischemia and anoxia, and relieving metabolic abnormality, hypofunction and structural change caused by the ischemia and anoxia; resisting oxidation, and relieving glomerular lipid peroxidation injury; anti-fibrosis, delay the development of glomerular sclerosis and protect the kidney function; calcium ion antagonism can relieve compensatory hypertrophy of glomerulus, inhibit mesangial cell proliferation and inhibit platelet aggregation.
The action mechanism of the astragalus is as follows: improving the plasma albumin, promoting the synthesis of muscle protein and liver protein and improving the whole body nutrition state; reduce proteinuria. The glomerulus filtration rate is improved, and the effects of inducing diuresis and relieving swelling are achieved; improving lipid metabolism, relieving glucose metabolism disorder, and improving hypercoagulability; anti-oxygen free radical effect; reduces glomerulosclerosis and renal interstitial fibrosis, and promotes the repair of tubular epithelial cell injury; the astragalus has a bidirectional regulating effect on an immune system, can restore disordered immune functions orderly, and is particularly beneficial to treating chronic renal failure for treating kidney diseases; research on patients with chronic nephritis shows that astragalus membranaceus can change the proportion of T lymphocyte subsets, improve the activity of natural killer cells and have a certain regulating effect on humoral immunity.
The composition for treating chronic renal failure combines the natto powder with the traditional Chinese medicine components, takes the screened natto powder generated by fermenting the bacillus subtilis as the main component, and is mutually cooperated with the rhubarb, the ligusticum chuanxiong hort and the astragalus according to a specific proportion, so that the composition has an obvious effect of treating chronic renal failure; the composition for treating chronic renal failure has the advantages of simple formula, no toxic or side effect and wide application prospect.
Preferably, the natto powder is prepared by the following process:
(1) preparing a peptone culture medium, and adding the following components in percentage by mass into the culture medium: 2% of peptone, 2% of glucose, 1% of disodium hydrogen phosphate, 0.1% of sodium dihydrogen phosphate, 0.05% of magnesium sulfate, 0.02% of anhydrous calcium chloride, 0.1% of defoaming agent and the balance of water, and sterilizing at 115 ℃ for 30min for later use;
(2) inoculating 1-3% of bacillus subtilis by weight into a peptone culture medium, and fermenting for 24h at 25-35 ℃;
(3) and removing impurities from the fermentation liquor, concentrating, and then performing spray drying to obtain the natto powder, wherein the activity of the natto powder is more than 80000 IU/g.
The embodiment of the invention also provides a preparation method of the composition for treating chronic renal failure, which comprises the following steps:
grinding natto powder, radix et rhizoma Rhei, rhizoma Ligustici Chuanxiong and radix astragali into powder, sieving, and mixing at a certain ratio to obtain the composition for treating chronic renal failure.
Preferably, the mesh number of the sieve is 80-100 meshes. After sieving, the components can be uniformly mixed by a three-dimensional mixer according to the mass percentage.
The embodiment of the invention also provides an application of a composition for treating chronic renal failure in treating chronic renal failure, wherein the composition for treating chronic renal failure comprises the following components in percentage by mass:
wherein the natto powder is produced by fermenting bacillus subtilis; the Bacillus subtilis is named as Bacillus subtilis QK02, is preserved by China Center for Type Culture Collection (CCTCC) and is positioned in Wuhan Hubei, the preservation number is CCTCC NO: M203078, and the preservation date is 11/17 days 2003.
The embodiment of the invention also provides a medicine, which comprises the composition for treating chronic renal failure prepared by the embodiment of the invention.
Preferably, the medicament further comprises any one or a combination of at least two of a pharmaceutically acceptable carrier, excipient or diluent.
The following is a further description with reference to specific examples.
Example 1
Embodiment 1 of the present invention provides a composition for treating chronic renal failure and a method for preparing the same.
A composition for treating chronic renal failure comprises the following components in percentage by mass:
the composition for treating chronic renal failure is prepared by the following method:
(1) preparing natto powder: adding the following components in percentage by mass into a culture medium: 2% of peptone, 2% of glucose, 1% of disodium hydrogen phosphate, 0.1% of sodium dihydrogen phosphate, 0.05% of magnesium sulfate, 0.02% of anhydrous calcium chloride, 0.1% of defoaming agent and the balance of water, and sterilizing at 115 ℃ for 30min for later use; inoculating bacillus subtilis to a peptone culture medium according to the weight ratio of 1%, and fermenting for 24h at 25 ℃; and removing impurities from the fermentation liquor, concentrating, and then performing spray drying to obtain the natto powder, wherein the activity of the natto powder is more than 80000 IU/g.
(2) Respectively grinding natto powder, rhubarb, ligusticum chuanxiong hort and astragalus membranaceus into powder, sieving the powder by a 80-mesh sieve, and uniformly mixing the powder in a three-dimensional mixer according to the proportion to obtain the composition for treating chronic renal failure.
Example 2
Embodiment 2 of the invention provides a composition for treating chronic renal failure and a preparation method thereof.
A composition for treating chronic renal failure comprises the following components in percentage by mass:
the composition for treating chronic renal failure is prepared by the following method:
the rhubarb, the ligusticum chuanxiong hort and the astragalus are respectively ground into powder, and the powder is sieved by a 80-mesh sieve and then uniformly mixed in a three-dimensional mixer according to the proportion to obtain the composition for treating chronic renal failure.
Example 3
Embodiment 3 of the invention provides a composition for treating chronic renal failure and a preparation method thereof.
A composition for treating chronic renal failure comprises the following components in percentage by mass:
the composition for treating chronic renal failure is prepared by the following method:
(1) preparing natto powder: adding the following components in percentage by mass into a culture medium: 2% of peptone, 2% of glucose, 1% of disodium hydrogen phosphate, 0.1% of sodium dihydrogen phosphate, 0.05% of magnesium sulfate, 0.02% of anhydrous calcium chloride, 0.1% of defoaming agent and the balance of water, and sterilizing at 115 ℃ for 30min for later use; inoculating bacillus subtilis into a peptone culture medium according to the weight ratio of 2%, and fermenting for 24h at 30 ℃; and removing impurities from the fermentation liquor, concentrating, and then performing spray drying to obtain the natto powder, wherein the activity of the natto powder is more than 80000 IU/g.
(2) Respectively grinding natto powder, rhubarb, ligusticum chuanxiong hort and astragalus membranaceus into powder, sieving the powder by a 100-mesh sieve, and uniformly mixing the powder in a three-dimensional mixer according to the proportion to obtain the composition for treating chronic renal failure.
Example 4
Embodiment 4 of the invention provides a composition for treating chronic renal failure and a preparation method thereof.
A composition for treating chronic renal failure comprises the following components in percentage by mass:
the composition for treating chronic renal failure is prepared by the following method:
(1) preparing natto powder: adding the following components in percentage by mass into a culture medium: 2% of peptone, 2% of glucose, 1% of disodium hydrogen phosphate, 0.1% of sodium dihydrogen phosphate, 0.05% of magnesium sulfate, 0.02% of anhydrous calcium chloride, 0.1% of defoaming agent and the balance of water, and sterilizing at 115 ℃ for 30min for later use; inoculating 3% of bacillus subtilis by weight into a peptone culture medium, and fermenting for 24h at 35 ℃; and removing impurities from the fermentation liquor, concentrating, and then performing spray drying to obtain the natto powder, wherein the activity of the natto powder is more than 80000 IU/g.
(2) Respectively grinding natto powder, rhubarb, ligusticum chuanxiong hort and astragalus membranaceus into powder, sieving the powder by a 100-mesh sieve, and uniformly mixing the powder in a three-dimensional mixer according to the proportion to obtain the composition for treating chronic renal failure.
Example 5
Embodiment 5 of the present invention provides a composition for treating chronic renal failure and a method for preparing the same.
A composition for treating chronic renal failure comprises the following components in percentage by mass:
the composition for treating chronic renal failure is prepared by the following method:
(1) preparing natto powder: adding the following components in percentage by mass into a culture medium: 2% of peptone, 2% of glucose, 1% of disodium hydrogen phosphate, 0.1% of sodium dihydrogen phosphate, 0.05% of magnesium sulfate, 0.02% of anhydrous calcium chloride, 0.1% of defoaming agent and the balance of water, and sterilizing at 115 ℃ for 30min for later use; inoculating bacillus subtilis into a peptone culture medium according to the weight ratio of 2%, and fermenting for 24h at 30 ℃; and removing impurities from the fermentation liquor, concentrating, and then performing spray drying to obtain the natto powder, wherein the activity of the natto powder is more than 80000 IU/g.
(2) Respectively grinding natto powder, rhubarb, ligusticum chuanxiong hort and astragalus membranaceus into powder, sieving the powder by a 90-mesh sieve, and uniformly mixing the powder in a three-dimensional mixer according to the proportion to obtain the composition for treating chronic renal failure.
Example 6
Embodiment 6 of the invention provides a composition for treating chronic renal failure and a preparation method thereof.
A composition for treating chronic renal failure comprises the following components in percentage by mass:
the composition for treating chronic renal failure is prepared by the following method:
(1) preparing natto powder: adding the following components in percentage by mass into a culture medium: 2% of peptone, 2% of glucose, 1% of disodium hydrogen phosphate, 0.1% of sodium dihydrogen phosphate, 0.05% of magnesium sulfate, 0.02% of anhydrous calcium chloride, 0.1% of defoaming agent and the balance of water, and sterilizing at 115 ℃ for 30min for later use; inoculating bacillus subtilis to a peptone culture medium according to the weight ratio of 1%, and fermenting for 24h at 35 ℃; and removing impurities from the fermentation liquor, concentrating, and then performing spray drying to obtain the natto powder, wherein the activity of the natto powder is more than 80000 IU/g.
(2) Respectively grinding natto powder, rhubarb, ligusticum chuanxiong hort and astragalus membranaceus into powder, sieving the powder by a 90-mesh sieve, and uniformly mixing the powder in a three-dimensional mixer according to the proportion to obtain the composition for treating chronic renal failure.
Application example
40 clean-grade Kunming mice were divided randomly into 4 groups of 10 mice each. Numbering a first group, a second group, a third group and a fourth group, wherein the first group is used as a control group and is fed normally; and (5) performing intragastric administration on the mice in the remaining three groups according to the dose of 200mg/Kg, and continuously performing intragastric administration for 10 days to construct the animal model of the chronic renal failure of the mice. After the construction is successful, the three groups of experimental groups are treated according to the set dosing scheme. And after the tenth day, mice of each group except the control group were subjected to intragastric adenine once every two days, continuously causing renal injury. Mice that were successfully constructed after 10 days of renal failure model mice were treated daily according to the following composition. Feeding at a dosage of 1.2 g/Kg.
Group 1 (control group): perfusing stomach with normal saline;
group 2: the medicine is administrated according to 200mg/Kg adenine dose every other day;
group 3: feeding the composition for treating chronic renal failure prepared in example 1 of the present invention, and administering the composition every other day at a dose of 200mg/Kg adenine;
group 4: the composition for treating chronic renal failure prepared in example 2 of the present invention was fed and administered every other day at a dose of 200mg/Kg adenine.
After 20 days of continuous administration, the animals are sacrificed, the body mass of each group is weighed, blood is taken from the orbit to separate serum, and the average mass is weighed by taking the double kidneys. Serum urea nitrogen (BUN) and creatinine (cr) content were measured. The measurement results are shown in table 1.
TABLE 1
| Group of | Body weight (g) | Weight of kidney | Cr(um/L) | BUN(mmol/L) |
| First group | 28.8±2.14 | 0.40±0.05 | 92.61±15.24 | 10.2±1.66 |
| Second group | 25.2±2.88 | 0.27±0.04 | 208.2±36.50 | 25.1±1.99 |
| Third group | 27.6±3.02 | 0.35±0.04 | 137.2±25.81 | 18.3±3.03 |
| Fourth group | 26.3±3.32 | 0.30±0.05 | 167.5±22.22 | 18.6±3.42 |
As can be seen from Table 1, the adenine model group quality and the kidney quality are both lower than those of the blank control group, and have significant differences, which indicates that the model construction is successful. In the composition fed with the natto powder-containing composition and the composition without the natto powder, the weight and the kidney weight are obviously higher than those of the adenine model group, and after the composition containing the natto powder is compared with the composition without the natto powder, the quality and the kidney weight of mice in the experimental group containing the natto powder are also higher than those in the group without the natto powder, and the differences are obvious.
In the compositions fed with the natto powder-containing composition and the composition without the natto powder, the blood urea nitrogen and the creatinine content are both obviously lower than those in the adenine model group, and after the composition containing the natto powder is compared with the composition without the natto powder, the blood urea nitrogen of the mice in the experimental group containing the natto powder is lower than that in the group without the natto powder and has obvious difference; the creatinine in mice in the group containing natto powder was less than in the group without natto powder. According to experimental data, the composition containing natto powder has obvious treatment effect on chronic renal failure mice.
The same method is used to verify the treatment effect of the compositions for treating chronic renal failure prepared in examples 3 to 6 of the present invention on chronic renal failure mice, and the same experimental conclusion as the present application is obtained, which indicates that the compositions for treating chronic renal failure prepared in examples of the present invention all have significant treatment effect on chronic renal failure mice.
The present invention is not limited to the above-described specific embodiments, and various modifications and variations are possible. Any modifications, equivalents, improvements and the like made to the above embodiments in accordance with the technical spirit of the present invention should be included in the scope of the present invention.
Claims (8)
1. The composition for treating chronic renal failure is characterized by comprising the following components in percentage by mass:
the natto powder is produced by fermenting bacillus subtilis; the bacillus subtilis is named as Subtilisin-QK and is preserved in the national culture collection center (CCTCC) with the preservation number of CCTCC NO: m203078, the preservation date was 2003.
2. The composition for treating chronic renal failure of claim 1, wherein the natto powder activity is > 80000 IU/g.
3. The composition for treating chronic renal failure of claim 2, wherein the natto powder is prepared by the process of:
preparing a peptone culture medium, and adding the following components in percentage by mass into the culture medium: 2% of peptone, 2% of glucose, 1% of disodium hydrogen phosphate, 0.1% of sodium dihydrogen phosphate, 0.05% of magnesium sulfate, 0.02% of anhydrous calcium chloride, 0.1% of defoaming agent and the balance of water, and sterilizing at 115 ℃ for 30min for later use;
inoculating 1-3% of bacillus subtilis by weight into the peptone culture medium, and fermenting for 24h at 25-35 ℃;
and removing impurities from the fermentation liquor, concentrating, and then performing spray drying to obtain the natto powder.
4. A method of preparing a composition for treating chronic renal failure, comprising the steps of:
grinding the natto powder, the rhubarb, the ligusticum chuanxiong hort and the astragalus membranaceus into powder, sieving the powder, and mixing the powder according to a proportion to obtain the composition for treating chronic renal failure.
5. The method for preparing the anti-aging composition according to claim 4, wherein the mesh number of the screen is 80-100 meshes.
6. The application of a composition for treating chronic renal failure in the treatment of chronic renal failure is characterized in that the composition for treating chronic renal failure contains the following components in percentage by mass:
the natto powder is produced by fermenting bacillus subtilis; the bacillus subtilis is named as Subtilisin-QK and is preserved in the national culture collection center (CCTCC) with the preservation number of CCTCC NO: m203078, the preservation date was 2003.
7. A medicament comprising a composition for treating chronic renal failure according to any one of claims 1 to 3.
8. The medicament of claim 7, further comprising any one or a combination of at least two of a pharmaceutically acceptable carrier, excipient or diluent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010762747.6A CN111840376A (en) | 2020-08-01 | 2020-08-01 | Composition for treating chronic renal failure and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010762747.6A CN111840376A (en) | 2020-08-01 | 2020-08-01 | Composition for treating chronic renal failure and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111840376A true CN111840376A (en) | 2020-10-30 |
Family
ID=72954138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010762747.6A Pending CN111840376A (en) | 2020-08-01 | 2020-08-01 | Composition for treating chronic renal failure and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111840376A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113558238A (en) * | 2021-07-28 | 2021-10-29 | 湖北真福医药有限公司 | Natto freeze-dried powder spina date seed solid beverage and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110038122A (en) * | 2019-05-23 | 2019-07-23 | 武汉真福医药股份有限公司 | Application of the hay bacillus fibrinolysin in treatment bronchitis drug |
| CN110368482A (en) * | 2019-07-18 | 2019-10-25 | 嫦娥创新（武汉）生物科技有限公司 | A kind of composition and its preparing the application in prevention and cure of cardiovascular disease drug |
-
2020
- 2020-08-01 CN CN202010762747.6A patent/CN111840376A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110038122A (en) * | 2019-05-23 | 2019-07-23 | 武汉真福医药股份有限公司 | Application of the hay bacillus fibrinolysin in treatment bronchitis drug |
| CN110368482A (en) * | 2019-07-18 | 2019-10-25 | 嫦娥创新（武汉）生物科技有限公司 | A kind of composition and its preparing the application in prevention and cure of cardiovascular disease drug |
Non-Patent Citations (4)
| Title |
|---|
| 《云南科普大讲坛·健康丛书》编委会: "《今天我们吃什么？》", 31 October 2011, 云南科技出版社 * |
| 佟芳等: "纳豆多糖改善小鼠IgA肾病的作用及其免疫学机制的研究分析", 《标记免疫分析与临床》 * |
| 师晶丽等: "芎芪颗粒防治肾小球硬化的实验研究", 《中华中医药杂志》 * |
| 张晔等: "《消化好 活得好》", 31 October 2016, 中国轻工业出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113558238A (en) * | 2021-07-28 | 2021-10-29 | 湖北真福医药有限公司 | Natto freeze-dried powder spina date seed solid beverage and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102048895B (en) | Pure traditional Chinese medicine preparation for treating dilated cardiomyopathy | |
| CN113413461A (en) | Medicine for resisting senile dementia and its preparing method | |
| WO2017129050A1 (en) | Medicament for use in treating asthma | |
| CN111840376A (en) | Composition for treating chronic renal failure and preparation method thereof | |
| CN103655599B (en) | Polysaccharide composition and application, containing its pharmaceutical preparation | |
| CN106806358A (en) | One seed ginseng wheat Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN114869953B (en) | Composition for resisting fatigue and enhancing immunity and treating rheumatism and preparation method thereof | |
| CN104352868B (en) | A kind of Chinese medicine preparation for treating pertussis | |
| CN111000947A (en) | Composition for reducing blood sugar and body fat and preparation method and application thereof | |
| CN1173726C (en) | Medicine for curing malignant turnor and its preparation method | |
| CN100528186C (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN1781538A (en) | Chinese medicine preparation for treating mephritis and nephrosis syndrome | |
| CN113332327A (en) | Application of American ginseng and astragalus preparation in preparing product for improving immunity | |
| CN114404433B (en) | Pinoresinol diglucoside composition for improving microcirculation and preparation method thereof | |
| CN105902867B (en) | A herbal composition for reducing hypertension, hyperglycemia and hyperlipidemia, and its preparation method | |
| CN108704105A (en) | A kind of Chinese medicine composition for treating Acute Cerebral Infarction | |
| CN1857531A (en) | Recipe, preparing process and application of Chinese medicine preparation for treating diabetic retinopathy | |
| CN103948666B (en) | Preparation method of Tibetan medicine for treating diabetes | |
| CN115531454B (en) | Application of composition as synergist for treating colpitis in preparation of medicines | |
| CN117281846B (en) | Traditional Chinese medicine composition for improving hypoxia tolerance and preparation method and application thereof | |
| CN114209059B (en) | Acanthopanax polysaccharide calcium and preparation method and application thereof | |
| CN100348247C (en) | Medicine used for treating inflammation of woman genetic system and its preparation method | |
| CN1287836C (en) | Chinese medicinal powder for treating diabetes and its production method | |
| CN107569576B (en) | Traditional Chinese medicine liver-nourishing and protecting compound preparation as well as preparation method and application thereof | |
| CN104784567B (en) | A kind of pharmaceutical composition for the treatment of urinary system infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201030 |
|
| RJ01 | Rejection of invention patent application after publication |